Open-Label, Randomized Study of Transition From Tacrolimus to Sirolimus Immunosuppression in Renal Allograft Recipients

Background. Calcineurin inhibitor-associated nephrotoxicity and other adverse events have prompted efforts to minimize/eliminate calcineurin inhibitor use in kidney transplant recipients. Methods. This open-label, randomized, multinational study evaluated the effect of planned transition from tacrolimus to sirolimus on kidney function in renal allograft recipients. Patients received tacrolimus-based immunosuppression and then were randomized 3 to 5 months posttransplantation to transition to sirolimus or continue tacrolimus. The primary end point was percentage of patients with 5 mL/min per 1.73 m(2) or greater improvement in estimated glomerular filtration rate from randomization to month 24. Results. The on-therapy population included 195 patients (sirolimus, 86tacrolimus, 109). No between-group difference was noted in percentage of patients with 5 mL/min per 1.73 m(2) or greater estimated glomerular filtration rate improvement (sirolimus, 34%tacrolimus, 42%P = 0.239) at month 24. Sirolimus patients had higher rates of biopsy-confirmed acute rejection (8% vs 2%P = 0.02), treatment discontinuation attributed to adverse events (21% vs 3%P < 0.001), and lower rates of squamous cell carcinoma of the skin (0% vs 5%P = 0.012). Conclusions. Our findings suggest that renal function improvement at 24 months is similar for patients with early conversion to sirolimus after kidney transplantation versus those remaining on tacrolimus.PfizerNovartisAstellasBristol-Myers SquibbRocheVeloxisQuarkHosp Rim, Div Nefrol, Sao Paulo, BrazilCalif Pacific Med Ctr, Dept Transplantat, San Francisco, CA USAHosp Clin San Carlos, Dept Nephrol, Madrid, SpainSt Lukes Med Ctr, Internal Med & Nephrol, Denver, CO USARoyal Adelaide Hosp, Renal & Transplant Serv, Adelaide, SA, AustraliaHosp Clin Barcelona, Dept Nephrol & Renal Transplantat, Barcelona, SpainPfizer, Global Innovat Pharma, Collegeville, PA USACSL Behring Biotherapies Life Clin Pharmacol & Ph, King Of Prussia, PA USAHosp Rim, Div Nefrol, Sao Paulo, BrazilWeb of Scienc